KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Accounts Payables: 2013-2025

Historic Accounts Payables for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $36.8 million.

  • Xenon Pharmaceuticals' Accounts Payables rose 30.14% to $36.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.8 million, marking a year-over-year increase of 30.14%. This contributed to the annual value of $34.2 million for FY2024, which is 31.75% up from last year.
  • Xenon Pharmaceuticals' Accounts Payables amounted to $36.8 million in Q3 2025, which was up 16.63% from $31.6 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Accounts Payables' 5-year high stood at $36.8 million during Q3 2025, with a 5-year trough of $7.6 million in Q1 2021.
  • For the 3-year period, Xenon Pharmaceuticals' Accounts Payables averaged around $28.2 million, with its median value being $28.3 million (2024).
  • Its Accounts Payables has fluctuated over the past 5 years, first fell by 6.23% in 2021, then skyrocketed by 166.81% in 2023.
  • Xenon Pharmaceuticals' Accounts Payables (Quarterly) stood at $13.7 million in 2021, then soared by 61.95% to $22.2 million in 2022, then rose by 16.93% to $26.0 million in 2023, then surged by 31.75% to $34.2 million in 2024, then skyrocketed by 30.14% to $36.8 million in 2025.
  • Its Accounts Payables was $36.8 million in Q3 2025, compared to $31.6 million in Q2 2025 and $30.6 million in Q1 2025.